Cargando…

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study

PURPOSE: The Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio predicts benefit from extended endocrine therapy in hormone receptor–positive (HR(+)) early-stage breast cancer. Here, we report the final analysis of the Trans-aTTom study examining BCI (H/I)'s predictive performance. EXPERIMENTA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartlett, John M.S., Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C., Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena F., Pirrie, Sarah J., Schnabel, Catherine A., Rea, Daniel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306281/ https://www.ncbi.nlm.nih.gov/pubmed/35144966 http://dx.doi.org/10.1158/1078-0432.CCR-21-3385

Ejemplares similares

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
por: Sgroi, Dennis C., et al.
Publicado: (2022)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
por: Bartlett, J M S, et al.
Publicado: (2019)

Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma
por: Nunes, Raquel, et al.
Publicado: (2021)

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

AttOmics: attention-based architecture for diagnosis and prognosis from omics data
por: Beaude, Aurélien, et al.
Publicado: (2023)

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021)

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial
por: Schwenzer, Hagen, et al.
Publicado: (2021)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2023)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Management of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children
por: Poon, Sarah W Y, et al.
Publicado: (2019)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
por: Tang, Zhe, et al.
Publicado: (2021)

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
por: Levin, Noam, et al.
Publicado: (2021)

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
por: Simonetta, Federico, et al.
Publicado: (2021)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Memory-like Differentiation Enhances NK Cell Responses to Melanoma
por: Marin, Nancy D., et al.
Publicado: (2021)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer
por: Servetto, Alberto, et al.
Publicado: (2021)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

IL13Rα2 Promotes Proliferation and Outgrowth of Breast Cancer Brain Metastases
por: Márquez-Ortiz, R. Alejandro, et al.
Publicado: (2021)

TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas
por: Gonzalez-Buendia, Edgar, et al.
Publicado: (2021)

DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
por: Venugopal, Kartika, et al.
Publicado: (2022)

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
por: Seeber, Andreas, et al.
Publicado: (2022)

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
por: Palmer, Adam C., et al.
Publicado: (2022)

Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
por: Hernandez, Sharia, et al.
Publicado: (2022)

Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
por: Sabbagh, Aria, et al.
Publicado: (2021)

Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer
por: Hashimoto, Ayumi, et al.
Publicado: (2021)

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021)

Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer
por: Peng, Hui, et al.
Publicado: (2021)

The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma
por: Sharma, Neeraj, et al.
Publicado: (2021)

Targeting Podoplanin for the Treatment of Osteosarcoma
por: Takemoto, Ai, et al.
Publicado: (2022)

Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
por: Vesely, Clare, et al.
Publicado: (2022)

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations
por: Shi, Qiong, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
por: Sheehan, Beshara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j61pdi473q5okpq5t7mj5rkq56